Studying immune cells in blood from people with lung diseases
Looks at immune cell responses in people with asthma, COPD, pneumonia or tuberculosis.
Plain-language title generated from the registry record
Registry title: Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
Key facts
- Where
- Borstel and Kiel, GermanySee the 2 sites
Where in Germany
- Medical Service Center MVZ, Research Center Borstel, Leibniz Lung CenterBorstel, GermanyNo longer taking part
- Department of Pulmonology, University Hospital Schleswig-HolsteinKiel, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Research Center Borstel
- Trial code
- NCT07386912
- Record updated
- 4 February 2026
- Original description
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.Read full original descriptionShow less
Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.
Inclusion: Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza); Age ≥ 18 years at the time of informed consent; Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation; Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.
Exclusion: Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses; Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding; Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable; Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture; Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations; Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.